Skip to content

13F-HR filed by Euclidean Capital LLC

Euclidean Capital LLC filed this 13F-HR for the quarter ended 2023-06-30, filed 2023-08-14, with 12 holding rows worth $389,143,221.

Accession
0001012975-23-000341
Filed
2023-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2023

A holdings report, 12 entries on the cover page, a total value of $389,143,221 stated on the cover page (in dollars after the unit check, H1), rows summing to $389,143,221 with VALUE read as dollars as filed, 13F file number 028-20777. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPY78462F103SHS246,250$109,157,700dollars as filed
ISHARES TR46429B598MSCI INDIA ETF2,425,144$105,978,793dollars as filed
SPDR GOLD TR78463V107GOLD SHS555,000$98,939,850dollars as filed
23ANDME HOLDING CO90138Q108CLASS A COM10,243,122$17,925,464dollars as filed
PMV PHARMACEUTICALS INC69353Y103COM2,545,242$15,933,215dollars as filed
FOGHORN THERAPEUTICS INC344174107COMMON STOCK1,573,761$11,079,277dollars as filed
RAPT THERAPEUTICS INC75382E109COM571,233$10,682,057dollars as filed
ALECTOR INC014442107COMMON STOCK980,894$5,895,173dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM747,550$5,800,988dollars as filed
TENAYA THERAPEUTICS INC87990A106COM915,705$5,375,188dollars as filed
NGM BIOPHARMACEUTICALS INC62921N105COM746,674$1,933,886dollars as filed
Surrozen, Inc.86889P109COM802,963$441,630dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-23-000341this filing2023-08-14acceptance time not in the bulk data set